Insider transactions

667, L.P.

CIK 1551139 · last filed 2026-06-29

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$6.85B
Companies
24
Total Filings
88
Lifetime Open-Market Net
$5.23B

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

BGNE price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
860 WASHINGTON STREET
3RD FLOOR
NEW YORK, NY 10014
Phone
(212) 339-5600
State of Incorporation
DE
Related Filers
Baker Brothers Life Sciences LP — 521 joint filings, latest 2026-08-11
BAKER BROS. ADVISORS LP — 520 joint filings, latest 2026-08-11
Felix Baker — 520 joint filings, latest 2026-08-11
Julian Baker — 520 joint filings, latest 2026-08-11
Baker Bros. Advisors (GP) LLC — 494 joint filings, latest 2026-08-11
14159, L.P. — 212 joint filings, latest 2019-10-03
Baker Bros. Investments, L.P. — 82 joint filings, latest 2019-10-03
Baker/Tisch Investments, LP — 82 joint filings, latest 2019-10-03
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
VTVT Director — $26.39 — $0 2 2026-06-29
ACAD Director 39,487,463 $19.75 $779.88M $630.00M 3 2026-06-02
ONC Director 730,643 $356.78 $260.68M -$1.57M 2 2026-05-27
TCRX Director — $0.19 — $0 3 2026-05-22
INCY Director 28,482,491 $114.51 $3.26B $0 11 2026-05-11
REPL Director — $12.38 — $0 1 2026-04-07
DBVT Director — $9.96 — $0 1 2026-01-14
KOD Director 18,358,772 $92.67 $1.70B $650.35M 7 2025-12-19
DNLI Director — $18.45 — $0 1 2025-12-15
MDGL Director 1,832,216 $438.20 $802.88M $196.74M 3 2025-08-20
IMCR Director — $31.16 — $0 1 2025-05-19
IGM Biosciences, Inc. (IGMS) Delisted Director 355,142 $1.27 $451.0K $0 9 2025-01-03
BCYC Director 8,666,247 $3.66 $31.72M $127.38M 2 2024-12-17
PRLD Director — $3.72 — $0 2 2024-06-18
BeOne Medicines Ltd. (BGNE) Delisted Director 126,096 $184.71 $23.29M $3.77B 2 2024-06-07
NGNE Director 39,081 $23.60 $922.3K $0 1 2023-12-20
Talis Biomedical Corp (TLIS) Delisted Director — $2.84 — $0 1 2023-06-13
KNSA Director 132,566 $86.32 $11.44M $0 2 2023-06-08
Seagen Inc. (SGEN) Delisted Director 43,000,581 $228.74 $9.84B $180.65M 5 2023-06-02
Neurogene Inc. (NLTX) Delisted Director — $13.96 — $0 1 2021-05-13
ZYME Director — $28.26 — $0 1 2020-05-12
GENOMIC HEALTH INC (GHDX) Delisted Director 157,519 — — -$482.48M 10 2019-04-12
Aceragen, Inc. (IDRA) Delisted Director 1,136 $7.22 $8.2K $224.00M 4 2018-06-21
XOMA Royalty Corp (XOMA) Delisted Director 104,451 $40.17 $4.20M -$59.06M 1 2015-01-06

Recent Filings · Page 7 of 9

88 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-04-03 IGM Biosciences, Inc. (IGMS) Delisted Grant (A) +2,676 $0 EDGAR
2019-07-02 INCY Grant (A) +3,720 $316.1K EDGAR
2019-04-30 INCY Grant (A) +31,920 $0 EDGAR
2019-04-12 GENOMIC HEALTH INC (GHDX) Delisted Sell (S) −112,040 -$7.32M EDGAR
2019-04-05 GENOMIC HEALTH INC (GHDX) Delisted Sell (S) −2,559,700 -$174.36M EDGAR
2019-01-30 GENOMIC HEALTH INC (GHDX) Delisted Sell (S) −464,770 -$33.03M EDGAR
2019-01-22 GENOMIC HEALTH INC (GHDX) Delisted Sell (S) −3,716,890 -$266.67M EDGAR
2019-01-14 GENOMIC HEALTH INC (GHDX) Delisted Sell (S) −392,590 -$27.57M EDGAR
2018-08-06 BeOne Medicines Ltd. (BGNE) Delisted Buy (P) +34,884,600 $3.77B EDGAR
2018-06-21 Aceragen, Inc. (IDRA) Delisted Grant (A) — $0 EDGAR
Showing 61–70 of 88
Page 7 of 9
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.